3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 3
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Classical hematology
2
Conditions
Lymphoproliferative Disorders
2
Anemia, Iron-Deficiency
2
Anemia
2
Neoplasms
1
Interventions
dacetuzumab
7
blinatumomab
6
Rituximab
5
ibrutinib
3
Cyclophosphamide
3
venetoclax
2
tetulomab tetraxetan lu-177
2
ponatinib
2
fludarabine
2
ferric carboxymaltose
2
cobomarsen
2
Vorinostat
2
Valganciclovir
2
Lutetium
2
Lenalidomide
2
Ifosfamide
2
Ganciclovir
2
Everolimus
2
Dexamethasone
2
Bortezomib
2
ruxolitinib
1
pomalidomide
1
pegaspargase
1
ficlatuzumab
1
epratuzumab
1
enzalutamide
1
durvalumab
1
denileukin diftitox
1
cirmtuzumab
1
asparaginase erwinia chrysanthemi recombinant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphoproliferative Disorders
×
ferric carboxymaltose
×
Clear all
NCT01100879
2022-05-09
AOC-MM
Vifor Pharma
Phase 4
Terminated
3 enrolled
NCT01101399
2013-12-18
FID-CHEMO
Vifor Pharma
Phase 3
Completed
19 enrolled